Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has made a key business development appointment in support of its ambitious growth plans.
News
OXFORD, UK February 21, 2022 – PrecisionLife Limited, a global techbio company driving precision medicine in chronic diseases with drug discovery, clinical development, and healthcare solutions based on its unique insights into disease biology, announces the appointment of Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the Company’s UK headquarters in Oxfordshire, UK.
Air Products is proud to announce that it has been awarded Medical Device Regulation (MDR) EC Mark certificate for Medical Device liquid nitrogen for the UK.
14 February 2022
Leading pharmaceutical and biotech product development consultancy Boyds has further strengthened its clinical expertise with the appointment of Pharmaceutical Physician, Dr Harriet Gray Stephens to its Clinical and Medical Affairs group.
A decade ago, EY created a metric, the Firepower Index, to understand how life sciences companies were most likely to use M&A to drive portfolio growth. I am pleased to share with you that our 2022 edition is now available. The report was launched on 10 January, during our virtual EY Firepower panels in conjunction with the annual JP Morgan Healthcare Conference.
Nottingham based contract research organisation (CRO) Cellomatics Biosciences has expanded its team with the appointment of senior molecular biologist, Dr Lara De Tomasi, in response to recent growth and the continued increase in demand for its bespoke preclinical and early discovery phase expertise.
London, UK, 10 February 2022: PharmaVentures today announced it has moved its operational headquarters from Oxford to London as part of its continued strategic expansion. The company will retain its remaining operational and administrative functions at its new registered office in Oxford.
Cambridge, United Kingdom, 10th February 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, today announces it has opened a facility of over 7,000 sq ft at Unity Campus in Sawston – Cambridge’s newest science and technology park encompassing Iconix Park and The Works, and owned by leading regional property and investment firm Howard Group.
The UK Government’s recently released “Levelling up White Paper” makes for interesting reading in the context of the life sciences sector.
In advance of a more in-depth review, here are some of the key points and my thoughts, focusing on two of the main areas of relevance to the sector: small company finance and R&D expenditure.